Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype

Keyphrases

• Stem Cells 100%
• Vascular Endothelial Growth Factor 100%
• Myeloid Cells 100%
• Anti-vascular Endothelial Growth Factor Therapy 100%
• Cell Infiltration 100%
• Cellular Accumulation 100%
• Mesenchymal Phenotype 100%
• Glioblastoma Resistance 100%
• Bevacizumab 80%
• Sunitinib 80%
• Tumor Vascularization 60%
• Hypoxia 40%
• Macrophages 40%
• Stem Cell Markers 40%
• VEGFR Inhibition 40%
• Growth Factor Sequestration 40%
• Flow Cytometry 20%
• Tumor 20%
• Antiangiogenic Agents 20%
• Immunohistochemistry 20%
• Marker Expression 20%
• CD11b 20%
• Signal Transduction Pathway 20%
• Cell Proliferation 20%
• Tumor Progression 20%
• Glioblastoma 20%
• Combination Treatment 20%
• Prolonged Survival 20%
• Tumor Hypoxia 20%
• VEGF Inhibitors 20%
• Infiltration 20%
• Differential Effects 20%
• Mesenchymal Cells 20%
• Treatment Resistance 20%
• Animal Survival 20%
• Relative Benefit 20%
• Relative Effectiveness 20%
• Response Mechanism 20%
• Orthotopic Tumor Growth 20%
• Mesenchymal Features 20%
• Re-infiltration 20%
• Bevacizumab Therapy 20%
• Orthotopic Glioma 20%
• Granulocyte Infiltration 20%
• Failure Mechanism 20%
• Angiogenesis Regulators 20%
• Proliferation Cell 20%
• Anti-VEGFR 20%

Immunology and Microbiology

• Stem Cell 100%
• Myeloid 100%
• Cell Infiltration 100%
• Vasculotropin 100%
• Bevacizumab 62%
• Sunitinib 50%
• Vascularization 37%
• Macrophage 25%
• Cell Marker 25%
• Granulocyte 12%
• Cell Proliferation 12%
• Angiogenesis Inhibitor 12%
• Angiogenesis 12%
• Signal Transduction 12%
• Tumor Hypoxia 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Vasculotropin 100%
• Glioblastoma 100%
• Bevacizumab 71%
• Neoplasm 57%
• Sunitinib 57%
• Hypoxia 42%
• Cell Marker 28%
• Tumor Growth 28%
• Angiogenesis Inhibitor 14%
• Vasculotropin Receptor 14%
• Flow Cytometry 14%
• Glioma 14%